

Conference call on the Report on Operations 2013

Invitation to attend Vitrolife's conference call regarding presentation of the Report on Operations 2013. The presentation will be held in English.

Time: Thursday, February 6, 2014 at 10.00 a.m. CET.

Registration can preferably be done in advance under the following link:

<https://eventreg1.conferencing.com/webportal3/reg.html?Acc=800440&Conf=189613>

or shortly before time of the conference starts on:

Sweden dial in number: +46 (0)8 5052 01 10

UK dial in number: +44 (0)20 7162 0077

Conference name: Vitrolife, conference ID: 940913

Vitrolife participants:

Thomas Axelsson, CEO

Mikael Engblom, CFO

The press release for Vitrolife's Year-end report will be released at 8.30 CET on the same day.

Before the conference call, slides will be available at the company web page,

<http://www.vitrolife.com/en/Corporate/>

A recorded version of the presentation will be available for seven days on number +46 (0)8 5052 0333 (Sweden) or 020 7031 4064 (UK), access code 940913.

Gothenburg, January 27, 2014

VITROLIFE AB (publ)

Contact:

Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife has approximately 230 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: 46 31 721 80 00. Fax: 46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.